Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

NCT07551778 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)
Colorectal Cancer
Advanced Solid Tumors

Interventions

BIOLOGICAL: NK Cells
BIOLOGICAL: NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy
BIOLOGICAL: NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy

Sponsor

BOE Technology Group Co., Ltd.